Inflamed actinic keratoses associated with pemetrexed and carboplatin therapy

Lam, Jimmy; Ellis, Samantha R.; Sivamani, Raja K

doi:10.5070/d32310037009

Cited by 3 publications

(1 citation statement)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observations of a beneficial effect of 5-fluorouracil-induced AK inflammation have already contributed to the successful registration of topical fluorouracil in the management of AK [ 1 , 2 ]. Besides pyrimidine analogs, a number of other chemotherapeutics, classified into chemotherapeutic groups of protein kinase inhibitors, taxanes, folic acid analogs, alkylating agents, platinum compounds, purine analogs, vinca alkaloids, cytotoxic antibiotics, and monoclonal antibodies, have been linked to similar reactions, suggesting potentially meaningful new pharmacodynamics mechanisms for further research [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. Here, we present two interesting new cases of inflammation of AK induced by chemotherapy with carboplatin and paclitaxel to add new evidence for their anti-AK effect.…”

Section: Introductionmentioning

confidence: 99%

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

et al. 2022

View full text Add to dashboard Cite

The observations of a beneficial effect of 5-fluorouracil-induced actinic keratoses (AK) inflammation led to the development of topical fluorouracil, a product registered for the management of AK. A conscientious surveillance of AK inflammation during chemotherapy may conceivably lead to the development of further drugs for treatment of AK. A number of other chemotherapeutics have thus been linked to similar reactions without ensuing development. Here, we describe two further cases linking chemotherapy with carboplatin and paclitaxel to possible anti-AK effects, identifying them as potential treatments. Whether multidrug chemotherapy leads to stronger AK inflammation or cure AK more successfully is currently unknown.

show abstract

Section: Introductionmentioning

confidence: 99%

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

et al. 2022

View full text Add to dashboard Cite

show abstract

Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis

Baglama

Peteln

Jemec

2022

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient

Khan,

Micho Ulbeh,

Zonder

et al. 2023

BMJ Case Rep

View full text Add to dashboard Cite

A man in his 60 s with a history of actinic keratosis (AK) and relapsed IgG kappa multiple myeloma (MM) recently received VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) chemotherapy and presented with numerous haemorrhagic, scaly lesions on his scalp and face. He also had sepsis from methicillin-sensitiveStaphylococcus aureus(MSSA) bacteraemia. Since the lesions were only present in the areas of pre-existing AK, a diagnosis of inflammation of AK secondary to chemotherapy was made. Sepsis was treated with appropriate antibiotics, and inflammation of AK was managed with topical steroids, leading to complete recovery.

show abstract

Inflamed actinic keratoses associated with pemetrexed and carboplatin therapy

Cited by 3 publications

References 8 publications

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports

Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis

Inflammation of actinic keratosis from chemotherapy in a relapsed multiple myeloma patient

Contact Info

Product

Resources

About